Payment overview · 2025
General Payments
$4,504.16
116 reported records · 24 companies
Healthcare provider profile · identity verified
Kai Mcgreevy, M.D
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ST AUGUSTINE, FL · NPI 1922208610
Verified facts
What the public records show
CMS Open Payments records show Kai Mcgreevy, M.D received $4,504.16 in general payments during 2025 across 116 reported records.
Abbott Laboratories accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,659.82 | 36.9% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $653.23 | 14.5% | 18 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $552.21 | 12.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $255.22 | 5.7% | 25 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $154.04 | 3.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.61 | 3.2% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $134.75 | 3.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $130.48 | 2.9% | 5 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $102.58 | 2.3% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $94.01 | 2.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $82.33 | 1.8% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $72.62 | 1.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $63.24 | 1.4% | 3 | 2025 |
| Spinal Simplicity, LLC | Unresolved — no canonical attribution shown | $59.61 | 1.3% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $51.39 | 1.1% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $49.91 | 1.1% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $43.01 | 0.9% | 2 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $38.69 | 0.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.56 | 0.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.14 | 0.8% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.82 | 0.6% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $23.43 | 0.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.86 | 0.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.60 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,645.63 | 106 |
| Travel and Lodging | $1,858.53 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $1,534.82 | 10 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $552.21 | 6 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $441.73 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $250.45 | 24 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $204.06 | 22 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.61 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $142.61 | 10 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $134.75 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $130.48 | 5 | 2025 |
Source payment records
|
|||||
| DURATA Normalized: durata |
Device | Abbott Laboratories | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $112.42 | 4 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $102.58 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $96.19 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $94.01 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $91.83 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $82.33 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $81.78 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $77.81 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $72.62 | 3 | 2025 |
Source payment records
|
|||||
| HA MINUTEMAN G3-R Normalized: ha minuteman g3 r |
Device | Spinal Simplicity, LLC | $59.61 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $58.29 | 2 | 2025 |
Source payment records
|
|||||
| EXCELSIUS GPS Normalized: excelsius gps |
Device | Globus Medical, Inc. | $57.85 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $51.39 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| COOLIEF COOLED RADIOFREQUENCY Normalized: coolief cooled radiofrequency |
Device | Avanos Medical | $38.69 | 1 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $34.38 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $34.14 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Infinion 16 Normalized: infinion 16 |
Device | Boston Scientific Corporation | $4.47 | 1 | 2025 |
Source payment records
|
|||||
| Bionic Navigator Normalized: bionic navigator |
Device | Boston Scientific Corporation | $3.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 684 | 112 |
| Gabapentin | Gabapentin | 531 | 139 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 392 | 64 |
| Oxycodone Hcl | Oxycodone Hcl | 312 | 38 |
| Tramadol Hcl | Tramadol Hcl | 249 | 51 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 210 | 57 |
| Pregabalin | Pregabalin | 203 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 189 | 44 |
| Donepezil Hcl | Donepezil Hcl | 171 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 170 | 30 |
| Topiramate | Topiramate | 156 | 46 |
| Methocarbamol | Methocarbamol | 120 | 27 |
| Meloxicam | Meloxicam | 94 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 21 |
| Levetiracetam | Levetiracetam | 87 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 87 | 12 |
| Fentanyl | Fentanyl | 70 | suppressed |
| Cephalexin | Cephalexin | 67 | 55 |
| Methylprednisolone | Methylprednisolone | 67 | 52 |
| Memantine Hcl | Memantine Hcl | 66 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 59 | suppressed |
| Alprazolam | Alprazolam | 57 | 11 |
| Baclofen | Baclofen | 53 | 12 |
| Propranolol Hcl | Propranolol Hcl | 53 | 17 |
| Primidone | Primidone | 51 | 20 |
| Diazepam | Diazepam | 48 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 27 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 24 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Ubrelvy | Ubrogepant | 20 | suppressed |
| Botox | Onabotulinumtoxina | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,504.16 · 116 records | Abbott Laboratories | AMPYRA, AMYVID, AUSTEDO XR, Bionic Navigator, COOLIEF COOLED RADIOFREQUENCY, DURATA, EXCELSIUS GPS, Evoke, General - Pain Management, General - Therapies, HA MINUTEMAN G3-R, HYQVIA, INBRIJA, Infinion 16, Intracept, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, PRECIVITYAD2, PROCLAIM, QULIPTA, REXULTI, SKYCLARYS, SPRINT PNS System, Senza, Symbravo, TONMYA, UBRELVY, VYEPTI, VYVGART, VYVGART HYTRULO, WaveWriter Alpha Prime 16, XYWAV, Xeomin, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error